New study shows that an experimental Alzheimer’s drug shows promise by targeting a different brain proteinap news
Biogen has presented Phase 2 CELIA data at the AAIC, demonstrating meaningful clinical results and robust tau reduction with diranersen in early Alzheimer’s disease.biogen
Biogen data highlight promise, questions surrounding tau-targeted Alzheimer’s drugsbiopharma dive
Study shows Biogen’s Alzheimer’s drug slowed decline at rates equal to approved treatmentsstate
AAIC: Biogen hopes to make significant Alzheimer’s push as anti-tau oligo slows cognitive declinefierce biotech
